AlloVir, Inc. (NASDAQ:ALVR) Short Interest Down 12.0% in December

AlloVir, Inc. (NASDAQ:ALVRGet Free Report) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 1,690,000 shares, a decrease of 12.0% from the November 30th total of 1,920,000 shares. Based on an average daily volume of 354,200 shares, the short-interest ratio is currently 4.8 days.

Institutional Investors Weigh In On AlloVir

A hedge fund recently bought a new stake in AlloVir stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of AlloVir, Inc. (NASDAQ:ALVRFree Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 76,278 shares of the company’s stock, valued at approximately $55,000. Point72 Asia Singapore Pte. Ltd. owned about 0.07% of AlloVir as of its most recent filing with the SEC. Institutional investors and hedge funds own 66.05% of the company’s stock.

AlloVir Trading Down 2.0 %

ALVR opened at $0.45 on Tuesday. The stock has a fifty day simple moving average of $0.62 and a two-hundred day simple moving average of $0.71. The company has a market cap of $51.76 million, a price-to-earnings ratio of -0.51 and a beta of 0.59. AlloVir has a 12-month low of $0.40 and a 12-month high of $1.05.

AlloVir (NASDAQ:ALVRGet Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10.

AlloVir Company Profile

(Get Free Report)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

Featured Articles

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.